Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Leaky Scanning02:28

Leaky Scanning

5.1K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.1K
Conjugated Proteins02:50

Conjugated Proteins

18.3K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
18.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global environmental and geo-economic impact of conservative versus liberal oxygen strategies in mechanically ventilated critically ill adults: an ecological country-level analysis.

British journal of anaesthesia·2026
Same author

Rethinking patient-ventilator asynchronies: toward a mechanism-based framework-Author's reply.

Intensive care medicine·2026
Same author

Feasibility and Reliability of an Automated Muscle Segmentation Pipeline Linking Thoracic Supine Kyphosis and Trunk Muscle-Fat% on CT.

Tomography (Ann Arbor, Mich.)·2026
Same author

Identification of a Quinolone-Based Scaffold as a Dual SARS-COV-2 PLᵖʳᵒ and Mᵖʳᵒ Inhibitor: An Integrated Molecular Modeling and In-vitro Evaluation Approach.

Drug design, development and therapy·2026
Same author

Artificial intelligence transforming healthcare research: opportunities, risks, and responsible use.

Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia·2026
Same author

Consensus on identifying and ranking ventilator asynchronies in invasively ventilated ICU patients: a modified Delphi study (SYNAPsE).

Intensive care medicine·2026

Related Experiment Video

Updated: Jun 20, 2025

A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation
07:53

A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation

Published on: January 9, 2019

33.2K

3-chymotrypsin-like protease in SARS-CoV-2.

Kenana Al Adem1, Juliana C Ferreira1, Adrian J Villanueva1

  • 1Science Division, New York University Abu Dhabi, PO Box 129188, Abu Dhabi, United Arab Emirates.

Bioscience Reports
|July 22, 2024
PubMed
Summary

Targeting the main protease (3CLpro) of SARS-CoV-2 is crucial for developing effective COVID-19 antiviral strategies. Inhibitors of 3CLpro block viral replication by preventing essential polyprotein cleavage.

Keywords:
3-chymotrypsin-like protease (3CLpro)COVID-19Covalent inhibitorsNon-covalent inhibitorsSARS-CoV-2main protease

More Related Videos

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
08:40

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

58.9K
Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

2.3K

Related Experiment Videos

Last Updated: Jun 20, 2025

A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation
07:53

A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation

Published on: January 9, 2019

33.2K
Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
08:40

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

58.9K
Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

2.3K

Area of Science:

  • Virology
  • Drug Discovery
  • Structural Biology

Background:

  • Coronaviruses, including SARS-CoV-2, pose a significant global health threat.
  • Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes the COVID-19 pandemic.
  • Effective antiviral therapies are urgently needed to combat widespread viral infections.

Purpose of the Study:

  • To review the structural and functional characteristics of SARS-CoV-2 3-chymotrypsin-like protease (3CLpro).
  • To highlight advancements in the development of 3CLpro inhibitors as antiviral treatments for COVID-19.
  • To provide a comprehensive resource on 3CLpro's role in the viral life cycle and therapeutic targeting.

Main Methods:

  • Literature review of studies on SARS-CoV-2 3CLpro structure and function.
  • Analysis of various inhibitor screening strategies, including peptide-like and small molecule approaches.
  • Examination of both active site and allosteric inhibition mechanisms against 3CLpro.

Main Results:

  • 3CLpro is a critical cysteine protease essential for SARS-CoV-2 replication.
  • Inhibitors targeting 3CLpro's active or allosteric sites effectively impede viral polyprotein processing.
  • Multiple 3CLpro inhibitors have been identified, with some already approved for clinical use.

Conclusions:

  • 3CLpro is a validated and vital target for antiviral drug development against SARS-CoV-2.
  • Targeting 3CLpro offers a promising strategy for managing COVID-19.
  • Continued research into 3CLpro inhibitors is essential for combating current and future coronavirus threats.